March 17 (Reuters) - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to ...

The partnership focuses on enhancing patient reach for cutting-edge diabetes care and chronic weight management solutions.

Global pharma major Lupin Limited (Lupin) has entered into a Licensing and Supply Agreement with Zydus Lifesciences Limited ...

Zydus Lifesciences and Lupin have entered into a licensing and supply agreement to co‑market a semaglutide injection in India ...

Under the Licensing and Supply Agreement signed by both companies, Lupin will have semi-exclusive rights to co-market Zydus’ ...

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping ...

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity ...

Lupin and Zydus partner to co-market semaglutide in India, entering a Rs 1,200 crore market with over 20 competitors and rapidly commoditising pricing dynamics.

As part of the deal, Lupin will pay Zydus upfront licensing fees and milestone-based payments linked to predefined targets.

Zydus Lifesciences and Lupin have partnered to co-market Semaglutide Injection, a weight-loss medication, in India ...

Zydus Lifesciences on Tuesday said it has entered into a licensing and supply agreement with Lupin to expand access of diabetes treatment drug Semaglutide Injection (15 mg/3 ml) with patient-friendly ...

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to ...